Arcus Biosciences, Inc.

Other

Dillon Harding Miles

Manmohan Reddy Leleti

Jay Patrick Powers

Brandon Reid Rosen

Ehesan Ul Sharif

Kenneth Victor Lawson

Jaroslaw Kalisiak

Erick Allen Lindsey

Eric Newcomb

Laurent Pierre Paul Debien

Jenna Leigh Jeffrey

Juan Carlos Jaen

Rhiannon Thomas-Tran

Joel Worley Beatty

Debashis Mandal

Laurent Debien

Ehesan Ui Sharif

Xuelei Yan

Samuel Lawrie Drew

Guillaume Mata

Artur Karenovich Mailyan

Balint Gal

Jeremy Thomas Andre Fournier

Corinne Nicole Foley

Srinivas Paladugu

Shiwei Qu

Ehesan U I Sharif

Manjunath Lamani

Laurent Pierre Debien

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Modulators of 5'-nucleotidase, ecto and the use thereof

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.

Compounds as inhibitors of AXL

Inhibitors of adenosine 5'-nucleotidase

Compound that inhibit at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Pyridone A2R antagonists

The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I),

Solid forms of an azolopyrimidine compound

Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form of Compound I and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5&#x2032;-nucleotidase, ecto is also provided.

Solid forms of a CD73 inhibitor and the use thereof

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5&#x2032;-nucleotidase, ecto is also provided.

Inhibitors of CD73-mediated immunosuppression

A compound that is an inhibitor of at least one of the Aand Aadenosine receptors having Formula (I) and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders

Compounds of Formula I that inhibit at least one of the Aand Aadenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Growing community of inventors

Berkeley, CA, United States of America

Dillon Harding Miles